Skip to main content
William Matsui, MD, Oncology, Austin, TX, Ascension Seton Medical Center Austin

WilliamHikaruMatsuiMD

Oncology Austin, TX

Hematologic Oncology

Professor of Oncology and Medicine Dell Medical School, University of Texas at Austin Deputy Director, LiveStrong Cancer Institutes

Dr. Matsui is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Matsui's full profile

Already have an account?

Summary

  • Dr. William Matsui is an oncologist in Austin, TX. He received his medical degree from University of California San Francisco School of Medicine and has been in practice 22 years. He specializes in hematologic oncology and is experienced in hematologic oncology, multiple myeloma, lymphoma, leukemia, and general medical oncology.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Medical Oncology, 1998 - 2002
  • University of Washington
    University of WashingtonResidency, Internal Medicine, 1995 - 1998
  • UCSF
    UCSFClass of 1995
  • Harvard College
    Harvard CollegeA.B., Biochemistry, With Honors, 1985 - 1989

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2018 - 2022
  • MD State Medical License
    MD State Medical License 1998 - 2019
  • WA State Medical License
    WA State Medical License 1997 - 1998
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2011
  • Elected Member The American Society for Clinical Investigation (ASCI), 2011
  • Leukemia and Lymphoma Society Scholar in Clinical Research The Leukemia and Lymphoma Society, 2009
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-vers...  
    Kanakry JA, Kasamon YL, Bolanos-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, Ghosh N, Gladstone DE, Gocke CD, Huff CA, Kanakry CG, Luznik L, Matsui W, Mogri HJ, Swinnen..., Biology Blood and Marrow Transplantation, 7/18/2013
  • Cancer stem cells in lung cancer: Evidence and controversies  
    Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN, Respirology, 7/1/2013
  • Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation  
    Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir A, Gustin JP, Rosen DM, Denmeade S, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessm..., Cancer Reserarch, 1/1/2013
  • Join now to see all

Press Mentions

  • MAX BioPharma Announces Key Update to Its Oncology Program and Oxysterol Lead Drug Candidates That Target Tumorigenic Signaling Pathways
    MAX BioPharma Announces Key Update to Its Oncology Program and Oxysterol Lead Drug Candidates That Target Tumorigenic Signaling PathwaysNovember 4th, 2019
  • Preliminary Study: Antibody Therapy Reduces Cancer Stem Cells in Multiple Myeloma
    Preliminary Study: Antibody Therapy Reduces Cancer Stem Cells in Multiple MyelomaApril 16th, 2016
  • Scientists Identify 'Mutation Accelerator' in Gene Mutation Linked to Common Adult Leukemia
    Scientists Identify 'Mutation Accelerator' in Gene Mutation Linked to Common Adult LeukemiaJune 10th, 2015
  • Join now to see all

Grant Support

  • Cancer Stem Cell Targeting In Multiple MyelomaNational Cancer Institute2008–2012
  • Myeloma Stem Cell Targeting By Liver X ReceptorsNational Cancer Institute2011
  • Cellular Diversity And Clinical Relevance Of Stem Cells In Pancreatic CancerNational Cancer Institute2011
  • Biology Of Multiple Myeloma Stem CellsNational Cancer Institute2005–2009

Professional Memberships

Hospital Affiliations